Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2010

View Archived Issues

Omeros receives USD 25 million in funding for GPCR program

Data from several studies on mitoxantrone for relapsing-remitting MS made available

Merck & Co. identifies new renin inhibitors

Clinical trials explore efficacy of budesonide in treating eosinophilic esophagitis

Effects of denosumab reported in patients with prostate cancer and bone metastases

AstraZeneca and Daiichi Sankyo announce agreement to copromote Nexium in Japan

Results reported from second phase III study of aclidinium bromide in COPD

FDA requests additional information from VIVUS regarding Qnexa NDA

Cellceutix completes final toxicity study of Kevetrin

Emergent BioSolutions acquires Trubion Pharmaceuticals

Neuron BioPharma describes new antioxidants/HMG-CoA reductase inhibitors

Third quarter highlights at Abbott

Teva Pharma to acquire Theramex, a women's health business, from Merck Serono

Acadia enters agreement with Biovail to regain rights to pimavanserin

Shire reports data from phase II Vyvanse study in major depressive disorder

Mild toxicity and disease stabilizations seen with L19TNF-alpha in patients with cancer

Merck Serono presents new lysophospholipid S1P1 receptor agonists

New inhibitors of Ras-related C3 botulinum toxin substrate 1 claimed

GSK and Amicus to develop Amigal for Fabry's disease

StemCells begins second clinical trial of HuCNS-SC in Batten disease

FDA approves Avanir's Nuedexta for treatment of pseudobulbar affect

Inhibitex begins phase Ib trial of INX-189 in chronic HCV infections

Spectrum Pharma submits additional data to FDA for Fusilev

FDA approves Afinitor as first treatment for benign brain tumor associated with tuberous sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...